Payment overview · 2025
General Payments
$1,785.75
124 reported records · 9 companies
Healthcare provider profile · identity verified
Heather Wells, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BOWLING GREEN, KY · NPI 1598306227
Verified facts
What the public records show
CMS Open Payments records show Heather Wells, APRN received $1,785.75 in general payments during 2025 across 124 reported records.
ABBVIE INC. accounted for 52.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $934.07 | 52.3% | 88 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $398.28 | 22.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $203.59 | 11.4% | 22 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $113.38 | 6.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.24 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.63 | 1.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.63 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.71 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.22 | 0.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,697.76 | 123 |
| Education | $87.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $568.64 | 43 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $381.85 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $365.43 | 45 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $361.08 | 44 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $187.76 | 21 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $165.51 | 20 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.22 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
98 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 565 | 170 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 294 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 64 |
| Montelukast Sodium | Montelukast Sodium | 210 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 207 | 57 |
| Ropinirole Hcl | Ropinirole Hcl | 193 | 45 |
| Furosemide | Furosemide | 192 | 54 |
| Lisinopril | Lisinopril | 175 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 42 |
| Metformin Hcl | Metformin Hcl | 168 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 38 |
| Potassium Chloride | Potassium Chloride | 138 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 31 |
| Azithromycin | Azithromycin | 122 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 31 |
| Omeprazole | Omeprazole | 111 | 41 |
| Losartan Potassium | Losartan Potassium | 110 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 98 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 98 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 90 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Eliquis | Apixaban | 88 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 75 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 16 |
| Meloxicam | Meloxicam | 74 | 20 |
| Sertraline Hcl | Sertraline Hcl | 74 | 19 |
| Trazodone Hcl | Trazodone Hcl | 74 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 59 | 17 |
| Simvastatin | Simvastatin | 59 | 18 |
| Ezetimibe | Ezetimibe | 57 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | 12 |
| Buspirone Hcl | Buspirone Hcl | 54 | 17 |
| Sucralfate | Sucralfate | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 43 |
| Theophylline Er | Theophylline Anhydrous | 53 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 19 |
| Famotidine | Famotidine | 50 | 19 |
| Gabapentin | Gabapentin | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Ozempic | Semaglutide | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 43 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 42 | 11 |
| Allopurinol | Allopurinol | 41 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Carvedilol | Carvedilol | 36 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Amoxicillin | Amoxicillin | 29 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 22 |
| Roflumilast | Roflumilast | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 14 |
| Armodafinil | Armodafinil | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,785.75 · 124 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, FANAPT, FARXIGA, HETLIOZ, NURTEC ODT, PREVNAR 20, QULIPTA, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, WAKIX, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error